Trials / Active Not Recruiting
Active Not RecruitingNCT04868838
Daratumumab to Treat Active Lupus Nephritis
A Phase 2 Open-label Trial Evaluating the Efficacy and Safety of Daratumumab in Treatment of Patients With Active Lupus Nephritis
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daratumumab | 1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. |
Timeline
- Start date
- 2021-04-20
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2021-05-03
- Last updated
- 2025-07-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04868838. Inclusion in this directory is not an endorsement.